Exploring Preferences and Priorities in Advanced Parkinson’s Disease: A Discrete Choice Experiment

Key findings from this study

This research indicates that:

• Persons with advanced Parkinson's disease prioritize on-without-dyskinesia duration as a primary treatment consideration.
• Route of administration represents a substantial secondary factor in treatment selection decisions.
• Patient preferences in advanced disease may warrant explicit incorporation into shared clinical decision-making processes.

Overview

This discrete choice experiment examined treatment preferences among persons with advanced Parkinson's disease (PwP). The study identified efficacy measured by on-without-dyskinesia (ONwoTD) time and route of administration as primary decision drivers in treatment selection.

Methods and approach

A discrete choice experiment methodology was employed to elicit stated preferences among PwP regarding advanced Parkinson's disease treatments. Respondents evaluated hypothetical treatment scenarios varying across multiple attributes including efficacy, route of administration, and other clinical parameters.

Results

PwP prioritized treatment efficacy as measured by ONwoTD duration when evaluating therapeutic options. Route of administration emerged as the second most important consideration in treatment decision-making.

These preference patterns suggest that individuals with advanced disease weight efficacy gains and practical administration factors heavily in their treatment evaluations. The relative importance of these attributes indicates distinct priorities that may differ from clinician perspectives or population-level health economic assumptions.

Implications

Clarifying patient priorities in advanced Parkinson's disease treatment selection may improve alignment between clinical recommendations and individual values. Incorporating explicit preference data into shared decision-making conversations could enhance treatment acceptability and adherence outcomes.

Healthcare providers should recognize that efficacy improvements in ON time and simplified or preferred administration routes substantially influence treatment decisions among PwP. Integration of these preference insights into clinical practice may support more patient-centered approaches to management in advanced disease stages.

Scope and limitations

This summary is based on the study abstract and available metadata. It does not include a full analysis of the complete paper, supplementary materials, or underlying datasets unless explicitly stated. Findings should be interpreted in the context of the original publication.